靶向治疗：阿法替尼——EGFR 突变型肺癌的新治疗选择。
Targeted therapies: Afatinib--new therapy option for EGFR-mutant lung cancer.
机构信息
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, Weill Cornell Medical College, 300 East 66th Street, New York, NY 10065, USA.
出版信息
Nat Rev Clin Oncol. 2013 Oct;10(10):551-2. doi: 10.1038/nrclinonc.2013.154. Epub 2013 Aug 20.
Abstract
On 15 July 2013, the FDA approved afatinib as a first-line treatment for patients with metastatic non-small-cell lung cancer whose tumours harbour exon 19 deletions or exon 21 (L858R) substitution mutations. We discuss three recent studies investigating afatinib in this molecular subset of patients.
摘要
2013 年 7 月 15 日，FDA 批准 afatinib 作为转移性非小细胞肺癌患者的一线治疗药物，这些患者的肿瘤具有外显子 19 缺失或外显子 21（L858R）取代突变。我们讨论了三项最近研究 afatinib 在这一分子亚组患者中的应用。
相似文献
1
Targeted therapies: Afatinib--new therapy option for EGFR-mutant lung cancer.靶向治疗：阿法替尼——EGFR 突变型肺癌的新治疗选择。
Nat Rev Clin Oncol. 2013 Oct;10(10):551-2. doi: 10.1038/nrclinonc.2013.154. Epub 2013 Aug 20.
2
[Molecular targeted therapies and cytotoxics: Friends or foes?].[分子靶向疗法与细胞毒性药物：是友还是敌？]
Bull Cancer. 2015 Jun;102(6 Suppl 1):S91-2. doi: 10.1016/S0007-4551(15)31223-6.
3
[Toxicity associated with EGRF inhibition: review and key aspects in the management of afatinib].[与表皮生长因子受体（EGFR）抑制相关的毒性：阿法替尼管理的综述及关键要点]
Med Clin (Barc). 2016 Apr;146 Suppl 1:30-5. doi: 10.1016/S0025-7753(16)30261-5.
4
EGFR -mutant non-small cell lung cancer patients harboring CDK4 amplification show favorable response to afatinib: Two case reports.携带CDK4扩增的表皮生长因子受体（EGFR）突变型非小细胞肺癌患者对阿法替尼表现出良好反应：两例病例报告。
Chin Med J (Engl). 2024 Jun 20;137(12):1465-1467. doi: 10.1097/CM9.0000000000003136. Epub 2024 May 21.
5
The Effectiveness of Afatinib in a Patient with Advanced Lung Adenocarcinoma Harboring Rare G719X and S768I Mutations.阿法替尼在一名携带罕见G719X和S768I突变的晚期肺腺癌患者中的疗效
Intern Med. 2018 Apr 1;57(7):993-996. doi: 10.2169/internalmedicine.9565-17. Epub 2017 Dec 8.
6
EGFR delE709_T710insD: a rare but potentially EGFR inhibitor responsive mutation in non-small-cell lung cancer.表皮生长因子受体（EGFR）E709_T710缺失并插入D：非小细胞肺癌中一种罕见但可能对EGFR抑制剂敏感的突变
J Thorac Oncol. 2012 Oct;7(10):e19-20. doi: 10.1097/JTO.0b013e3182635ab4.
7
New kinase inhibitor approved for metastatic lung cancer.新型激酶抑制剂获批用于治疗转移性肺癌。
Am J Health Syst Pharm. 2013 Aug 15;70(16):1363. doi: 10.2146/news130055.
8
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.晚期表皮生长因子受体（EGFR）突变阳性非鳞状非小细胞肺癌的一线治疗
Cochrane Database Syst Rev. 2016 May 25(5):CD010383. doi: 10.1002/14651858.CD010383.pub2.
9
[Afatinib in patients with squamous cell carcinoma of the lung: current context and the option of oral treatment].[阿法替尼用于肺鳞状细胞癌患者：当前情况及口服治疗选择]
Med Clin (Barc). 2016 Apr;146 Suppl 1:25-9. doi: 10.1016/S0025-7753(16)30260-3.
10
Erlotinib response in an NSCLC patient with a novel compound G719D+L861R mutation in EGFR.一名非小细胞肺癌患者携带表皮生长因子受体（EGFR）新型复合突变G719D+L861R对厄洛替尼的反应
J Thorac Oncol. 2013 Sep;8(9):e83-4. doi: 10.1097/JTO.0b013e31829ceb8d.
引用本文的文献
1
Intracellular cholesterol: new functions and therapeutic approaches in NSCLC EGFR-TKI resistance.细胞内胆固醇：非小细胞肺癌表皮生长因子受体酪氨酸激酶抑制剂耐药中的新功能与治疗方法
Lipids Health Dis. 2025 Jul 30;24(1):255. doi: 10.1186/s12944-025-02559-w.
2
Growth factor-triggered de-sialylation controls glycolipid-lectin-driven endocytosis.生长因子触发的去唾液酸化作用控制糖脂-凝集素驱动的内吞作用。
Nat Cell Biol. 2025 Mar;27(3):449-463. doi: 10.1038/s41556-025-01616-x. Epub 2025 Feb 21.
3
Virtual Screening and Biological Evaluation of T22306 as a Potent Third-generation EGFR Inhibitor for NSCLC Treatment.T22306作为一种用于非小细胞肺癌治疗的强效第三代表皮生长因子受体抑制剂的虚拟筛选及生物学评价
Anticancer Agents Med Chem. 2025;25(15):1128-1141. doi: 10.2174/0118715206362954250203103859.
4
Design, synthesis, docking, ADMET and anticancer evaluations of -alkyl substituted iodoquinazoline derivatives as dual VEGFR-2 and EGFR inhibitors.-烷基取代碘喹唑啉衍生物作为双 VEGFR-2 和 EGFR 抑制剂的设计、合成、对接、ADMET 和抗癌评估
RSC Adv. 2023 Dec 13;13(51):36301-36321. doi: 10.1039/d3ra07700d. eCollection 2023 Dec 8.
5
Neoadjuvant Afatinib for stage III EGFR-mutant non-small cell lung cancer: a phase II study.阿法替尼新辅助治疗 III 期 EGFR 突变非小细胞肺癌：一项 II 期研究。
Nat Commun. 2023 Aug 3;14(1):4655. doi: 10.1038/s41467-023-40349-z.
6
Role of EGFR and FASN in breast cancer progression.表皮生长因子受体（EGFR）和脂肪酸合酶（FASN）在乳腺癌进展中的作用。
J Cell Commun Signal. 2023 Dec;17(4):1249-1282. doi: 10.1007/s12079-023-00771-w. Epub 2023 Jul 25.
7
Nitrogen Containing Heterocycles as Anticancer Agents: A Medicinal Chemistry Perspective.含氮杂环作为抗癌剂：药物化学视角
Pharmaceuticals (Basel). 2023 Feb 14;16(2):299. doi: 10.3390/ph16020299.
8
Structure-Guided Strategies of Targeted Therapies for Patients with -Mutant Non-Small Cell Lung Cancer.基于结构的 - 突变型非小细胞肺癌靶向治疗策略。
Biomolecules. 2023 Jan 20;13(2):210. doi: 10.3390/biom13020210.
9
Biomarker-Targeted Therapies in Non-Small Cell Lung Cancer: Current Status and Perspectives.生物标志物靶向治疗非小细胞肺癌：现状与展望。
Cells. 2022 Oct 12;11(20):3200. doi: 10.3390/cells11203200.
10
Advances in covalent drug discovery.共价药物发现的进展。
Nat Rev Drug Discov. 2022 Dec;21(12):881-898. doi: 10.1038/s41573-022-00542-z. Epub 2022 Aug 25.
本文引用的文献
1
Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.LUX-Lung 3 研究：阿法替尼或顺铂/培美曲塞治疗伴有 EGFR 突变的晚期肺腺癌患者的 III 期研究：症状控制和生活质量。
J Clin Oncol. 2013 Sep 20;31(27):3342-50. doi: 10.1200/JCO.2012.46.1764. Epub 2013 Jul 1.
2
LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both.LUX-Lung 4 研究：阿法替尼治疗既往接受厄洛替尼、吉非替尼或两者联合治疗后进展的晚期非小细胞肺癌患者的 II 期临床试验。
J Clin Oncol. 2013 Sep 20;31(27):3335-41. doi: 10.1200/JCO.2012.45.0981. Epub 2013 Jul 1.
3
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.III 期研究阿法替尼或顺铂加培美曲塞治疗 EGFR 突变的转移性肺腺癌患者。
J Clin Oncol. 2013 Sep 20;31(27):3327-34. doi: 10.1200/JCO.2012.44.2806. Epub 2013 Jul 1.
4
Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.155 例 EGFR 突变型肺癌患者获得性 EGFR-TKI 治疗耐药时的肿瘤标本分析。
Clin Cancer Res. 2013 Apr 15;19(8):2240-7. doi: 10.1158/1078-0432.CCR-12-2246. Epub 2013 Mar 7.
5
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.阿法替尼对比安慰剂用于厄洛替尼、吉非替尼治疗失败或两者都失败，以及一线或二线化疗后进展、转移性非小细胞肺癌患者（LUX-Lung 1）：一项 2b/3 期随机试验。
Lancet Oncol. 2012 May;13(5):528-38. doi: 10.1016/S1470-2045(12)70087-6. Epub 2012 Mar 26.
6
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.厄洛替尼对比标准化疗用于治疗欧洲晚期 EGFR 突变阳性非小细胞肺癌患者的一线治疗（EURTAC）：一项多中心、开放标签、随机、3 期临床试验。
Lancet Oncol. 2012 Mar;13(3):239-46. doi: 10.1016/S1470-2045(11)70393-X. Epub 2012 Jan 26.
7
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.厄洛替尼对比化疗用于治疗晚期 EGFR 突变阳性非小细胞肺癌患者的一线治疗（OPTIMAL、CTONG-0802）：一项多中心、开放标签、随机、III 期研究。
Lancet Oncol. 2011 Aug;12(8):735-42. doi: 10.1016/S1470-2045(11)70184-X. Epub 2011 Jul 23.
8
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer.基于理性和生物学原理的 EGFR 突变型非小细胞肺癌治疗。
Nat Rev Cancer. 2010 Nov;10(11):760-74. doi: 10.1038/nrc2947. Epub 2010 Oct 22.
9
Erlotinib in previously treated non-small-cell lung cancer.厄洛替尼用于既往接受过治疗的非小细胞肺癌。
N Engl J Med. 2005 Jul 14;353(2):123-32. doi: 10.1056/NEJMoa050753.
Zotero 插件